Skip to content

Study on the diagnostic value of metagenomic next generation sequencing (mNGS) based on respiratory intervention in pulmonary infection

Study on the diagnostic value of metagenomic next generation sequencing (mNGS) based on respiratory intervention in pulmonary infection

Status
Active, not recruiting
Phases
Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2200058998
Enrollment
Unknown
Registered
2022-04-22
Start date
2022-04-22
Completion date
Unknown
Last updated
2024-02-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

pulmonary infection

Interventions

Gold Standard:Clinical manifestations and chest CT signs
Index test:CT guided lung biopsy

Sponsors

Zhoukou Central Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Aged >18 years; 2. Clinical manifestations include low fever, cough, phlegm, chest tightness, chest pain, hemoptysis and other clinical symptoms and signs; 3. Chest CT indicated nodules or consolidation and exudation with imaging features, and after anti-infective treatment for 1 week, CT reexamination showed no obvious absorption of the lesions, which required further clarification of etiological diagnosis; 4. No culture-positive bacteria were found in the conventional sputum smears; 5. Agree to perform CT-guided lung puncture biopsy and sign informed consent, and agree to participate in this study and sign informed consent.

Exclusion criteria

Exclusion criteria: 1. The patient could not tolerate tracheoscopy or CT-guided lung puncture; 2. The patient had poor coagulation function, the indexes related to coagulation function and blood routine did not meet the inclusion criteria, or the respiratory tract showed serious bleeding symptoms; 3. Patients with acute heart failure, severe asthma, unstable angina and other serious underlying diseases; 4. Recently taking anticoagulant drugs, antiplatelet drugs or drugs to promote blood circulation and remove blood stasis; 5. Allergies to narcotic drugs.

Design outcomes

Primary

MeasureTime frame
diagnosic yield;

Secondary

MeasureTime frame
complication;

Countries

China

Contacts

Public ContactLiu Yong

Zhoukou Central Hospital

zyliu04@sina.com+86 13526258730

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026